We presented the rationale for the use of thymosin alpha1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase(Eudract no.2020-006020-13). We aim to offer new hope for this incurable disease, especially to frail patient population, such as patients with cancer. The hypothesis of an effective prophylactic approach to COVID-19 would have immediate clinical relevance, especially given the lack of curative approaches. Moreover, in the 'COVID-19 vaccine race era' both clinical and biological results coming from the PROTHYMOS trials could even support the rationale for future combinatorial approaches, trying to rise vaccine efficacy in frail individuals.

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients / Bersanelli, Melissa; Giannarelli, Diana; Leonetti, Alessandro; Buti, Sebastiano; Tiseo, Marcello; Nouvenne, Antonio; Ticinesi, Andrea; Meschi, Tiziana; Procopio, Giuseppe; Danielli, Riccardo. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 17:9(2021), pp. 1097-1104. [10.2217/fon-2020-0754]

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients

Bersanelli, Melissa
;
Leonetti, Alessandro;Buti, Sebastiano;Tiseo, Marcello;Nouvenne, Antonio;Ticinesi, Andrea;Meschi, Tiziana;
2021

Abstract

We presented the rationale for the use of thymosin alpha1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase(Eudract no.2020-006020-13). We aim to offer new hope for this incurable disease, especially to frail patient population, such as patients with cancer. The hypothesis of an effective prophylactic approach to COVID-19 would have immediate clinical relevance, especially given the lack of curative approaches. Moreover, in the 'COVID-19 vaccine race era' both clinical and biological results coming from the PROTHYMOS trials could even support the rationale for future combinatorial approaches, trying to rise vaccine efficacy in frail individuals.
File in questo prodotto:
File Dimensione Formato  
Bersanelli Future Oncology 2021.pdf

accesso aperto

Descrizione: Full Text
Tipologia: Versione (PDF) editoriale
Licenza: Creative commons
Dimensione 1.53 MB
Formato Adobe PDF
1.53 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2888839
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact